Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimkibart in Moderately to Severely Active Ulcerative Colitis
NCT07846683Phase 3Recruiting
- Sponsor
- Roche
- Start
- Nov 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
A Phase 3 trial of afimkibart in ulcerative colitis (UC), sponsored by Roche. Started Nov 2026; status: recruiting.
02
Drugs
afimkibart
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07846683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07846683.